High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: Long term results for 105 patients

Cancer

Volumn 85, Issue 7, 1999, Pages 1555-1564

  Shinozuka, Takao ^a   Miyamoto, Tsuyoshi ^a   Muramatsu, Toshinari ^a   Hirasawa, Takeshi ^a   Murakami, Masaru ^a   Makino, Tsunehisa ^a   Tanaka, Yutaka ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autologous bone marrow transplantation; High dose chemotherapy; Long term follow up; Ovarian carcinoma; Prognostic factor

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0033120678     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990401)85:7<1555::AID-CNCR17>3.0.CO;2-4     Document Type: Article

References (34)

1. Wiltshaw E, Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 1976;60:55-60.
2. Bruckner HW, Ratner LH, Cohen CJ, Wallach R, Kabakow B, Greenspan EM, et al. Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammine-platinum(II) after failure of initial chemotherapy. Cancer Treat Rep 1978;62:1021-3.
3. Ehrlich CE, Einhorn L, Williams SD, Morgan J. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report. Cancer Treat Rep 1979;63:281-8.
4. Williams CJ, Stevenson KE, Buchanan RB, Whitehouse JMA. Advanced ovarian carcinoma: a pilot study of cis-dichlorodiammineplatinum(II) in combination with adriamycin and cyclophosphamide in previously untreated patients and as a single agent in previously treated patients. Cancer Treat Rep 1979;63:1745-53.
5. Bruckner HW, Wallach R, Cohen CJ, Deppe G, Kabakow B, Ratner L, et al. High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol 1981;12:64-7.
6. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985;3:1246-50.
7. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.
8. Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 1984;18:293-8.
9. Tobias JS, Weiner RS, Griffiths CT, Richman CM, Parker LM, Yankee RA. Cryopreserved autologous marrow infusion following high dose cancer chemotherapy. Eur J Cancer 1977; 13:269-77.
10. Vriesendorp AR, Aalders JG, Sleijfer DT, Postmus PE, Willemse PHB, Bouma J, et al. Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. Gynecol Oncol 1984;17:271-6.
11. Murakami M, Shinozuka T, Kuroshima Y, Tokuda Y, Tajima T. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumors. Semin Oncol 1994;21(Suppl 1):S1-29-32.
12. Shinozuka T, Murakami M, Miyamoto T, Fujii A, Tokuda Y, Tajima T, et al. High dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) in ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1991;10:193.
13. Shinozuka T, Miyamoto T, Muramatsu T, Hirasawa T, Murakami M, Tanaka Y, et al. Long-term follow-up and prognostic analysis in epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin, and cisplatin (CAP) with autologous bone marrow transplantation (ABMT) [abstract]. Proc Am Soc Clin Oncol 1997;16:378a.
14. Gilmore MJML, Prentice HG, Blacklock HA, Ma DDF, Janossy G, Hoffbrand AV. A technique for rapid isolation of bone marrow mononuclear cells using Ficoll-Metrizonate and the JBM 2991 blood cell processor. Br J Haematol 1982; 50:619-26.
15. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-50.
16. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991;303:884-93.
17. Gloeckler Ries LA. Ovarian cancer. Cancer 1993;71:524-9.
18. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
19. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995;13:1589-99.
20. Colombo N, Pittelli MR, Parma G, Marzola M, Torri W, Mangioni C. Cisplatin (P) dose intensity in advanced ovarian cancer (AOC): a randomized study of conventional dose (CD) vs dose intense (DI) cisplatin monochemotherapy [abstract]. Proc Am Soc Clin Oncol 1993;12:255.
21. Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996;14:351-6.
22. Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997;15:193-8.
23. Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, et al. Mature results of randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14:2113-9.
24. Fennelly D, Wasserheit C, Schneider J, Hakes T, Reich L, Curtin J, et al. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cell and filgrastim: a phase I trial. Cancer Res 1994;54:6137-42.
25. Fennelly DW, Aghajanian C, Shapiro F, O'Flaherty C, O'Connor K, Curtin JP, et al. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Semin Oncol 1997;24(Suppl 2):S2-26-30.
26. Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, et al. A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol 1995;57:278-85.
27. Benedetti-Panici P, Greggi S, Scambia G, Salerno MG, Menichella G, Pierelli L, et al. High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Ann Med 1995;27:133-8.
28. Conte PF, Bruzzone M, Carnino F, Chrara S, Donadio M, Racchini V, et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1991;9:658-63.
29. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-26.
30. Legros M, Dauplat J, Fleury J, Cure H, Suzanne F, Chassagne J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997;15:1302-8.
31. Stiff PJ, Bayer R, Kerger C, Patkul RK, Malhotra D, Peace DJ, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997;15:1309-17.
32. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.
33. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
34. Wandt H, Birkmann J, Schaefer-Eckart K, Denzel T, Gallmeier WM, Pilz D, et al. Sequential cycles of high-dose chemotherapy supported by G-CSF (filgrastim) mobilized peripheral blood progenitor cells (PBPC) in advanced ovarian cancer: A phase I/II dose escalation study for carboplatin [abstract]. Proc Am Soc Clin Oncol 1997;16:92a.